210 related articles for article (PubMed ID: 35950920)
1. A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer.
Nardone A; Qiu X; Spisak S; Nagy Z; Feiglin A; Feit A; Cohen Feit G; Xie Y; Font-Tello A; Guarducci C; Hermida-Prado F; Syamala S; Lim K; Munoz Gomez M; Pun M; Cornwell M; Liu W; Ors A; Mohammed H; Cejas P; Brock JB; Freedman ML; Winer EP; Fu X; Schiff R; Long HW; Metzger Filho O; Jeselsohn R
Cancer Res; 2022 Oct; 82(20):3673-3686. PubMed ID: 35950920
[TBL] [Abstract][Full Text] [Related]
2. A Unique FOXA1-Associated Chromatin State Dictates Therapeutic Resistance in Lobular Breast Cancer.
Blawski R; Toska E
Cancer Res; 2022 Oct; 82(20):3668-3670. PubMed ID: 36245246
[TBL] [Abstract][Full Text] [Related]
3. Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response.
Sikora MJ; Cooper KL; Bahreini A; Luthra S; Wang G; Chandran UR; Davidson NE; Dabbs DJ; Welm AL; Oesterreich S
Cancer Res; 2014 Mar; 74(5):1463-74. PubMed ID: 24425047
[TBL] [Abstract][Full Text] [Related]
4. Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer.
Sokol ES; Feng YX; Jin DX; Basudan A; Lee AV; Atkinson JM; Chen J; Stephens PJ; Frampton GM; Gupta PB; Ross JS; Chung JH; Oesterreich S; Ali SM; Hartmaier RJ
Ann Oncol; 2019 Jan; 30(1):115-123. PubMed ID: 30423024
[TBL] [Abstract][Full Text] [Related]
5. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
[TBL] [Abstract][Full Text] [Related]
6. Mediator of DNA Damage Checkpoint 1 (MDC1) Is a Novel Estrogen Receptor Coregulator in Invasive Lobular Carcinoma of the Breast.
Sottnik JL; Bordeaux EK; Mehrotra S; Ferrara SE; Goodspeed AE; Costello JC; Sikora MJ
Mol Cancer Res; 2021 Aug; 19(8):1270-1282. PubMed ID: 33947745
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Review of Molecular Mechanisms and Clinical Features of Invasive Lobular Cancer.
Pramod N; Nigam A; Basree M; Mawalkar R; Mehra S; Shinde N; Tozbikian G; Williams N; Majumder S; Ramaswamy B
Oncologist; 2021 Jun; 26(6):e943-e953. PubMed ID: 33641217
[TBL] [Abstract][Full Text] [Related]
8. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines.
Sikora MJ; Jacobsen BM; Levine K; Chen J; Davidson NE; Lee AV; Alexander CM; Oesterreich S
Breast Cancer Res; 2016 Sep; 18(1):92. PubMed ID: 27650553
[TBL] [Abstract][Full Text] [Related]
9. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
10. Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities.
Stires H; Heckler MM; Fu X; Li Z; Grasso CS; Quist MJ; Lewis JA; Klimach U; Zwart A; Mahajan A; Győrffy B; Cavalli LR; Riggins RB
Mol Cell Endocrinol; 2018 Aug; 471():105-117. PubMed ID: 28935545
[TBL] [Abstract][Full Text] [Related]
11. SNAIL is induced by tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma.
Bossart EA; Tasdemir N; Sikora MJ; Bahreini A; Levine KM; Chen J; Basudan A; Jacobsen BM; Burns TF; Oesterreich S
Breast Cancer Res Treat; 2019 Jun; 175(2):327-337. PubMed ID: 30798422
[TBL] [Abstract][Full Text] [Related]
12. Chromatin accessibility landscape and active transcription factors in primary human invasive lobular and ductal breast carcinomas.
Lee S; Osmanbeyoglu HU
Breast Cancer Res; 2022 Jul; 24(1):54. PubMed ID: 35906698
[TBL] [Abstract][Full Text] [Related]
13. Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis.
van de Water W; Fontein DB; van Nes JG; Bartlett JM; Hille ET; Putter H; Robson T; Liefers GJ; Roumen RM; Seynaeve C; Dirix LY; Paridaens R; Kranenbarg EM; Nortier JW; van de Velde CJ
Eur J Cancer; 2013 Jan; 49(2):297-304. PubMed ID: 22954666
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer.
Ciriello G; Gatza ML; Beck AH; Wilkerson MD; Rhie SK; Pastore A; Zhang H; McLellan M; Yau C; Kandoth C; Bowlby R; Shen H; Hayat S; Fieldhouse R; Lester SC; Tse GM; Factor RE; Collins LC; Allison KH; Chen YY; Jensen K; Johnson NB; Oesterreich S; Mills GB; Cherniack AD; Robertson G; Benz C; Sander C; Laird PW; Hoadley KA; King TA; ; Perou CM
Cell; 2015 Oct; 163(2):506-19. PubMed ID: 26451490
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer.
Richard F; Majjaj S; Venet D; Rothé F; Pingitore J; Boeckx B; Marchio C; Clatot F; Bertucci F; Mariani O; Galant C; Eynden GVD; Salgado R; Biganzoli E; Lambrechts D; Vincent-Salomon A; Pruneri G; Larsimont D; Sotiriou C; Desmedt C
Clin Cancer Res; 2020 Dec; 26(23):6254-6265. PubMed ID: 32943456
[TBL] [Abstract][Full Text] [Related]
16. Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors.
Truin W; Roumen RMH; Siesling S; van de Vijver KK; Tjan-Heijnen VCG; Voogd AC
Breast Cancer Res Treat; 2017 Jul; 164(1):133-138. PubMed ID: 28365833
[TBL] [Abstract][Full Text] [Related]
17. Survival analysis in patients with invasive lobular cancer and invasive ductal cancer according to hormone receptor expression status in the Korean population.
Kwon D; Ko BK; Jung SP; Kim HK; Kim EK; Jung YS; Youn HJ; Lee SB
PLoS One; 2022; 17(1):e0262709. PubMed ID: 35051228
[TBL] [Abstract][Full Text] [Related]
18. Mixed invasive ductal and lobular carcinoma has distinct clinical features and predicts worse prognosis when stratified by estrogen receptor status.
Xiao Y; Ma D; Ruan M; Zhao S; Liu XY; Jiang YZ; Shao ZM
Sci Rep; 2017 Sep; 7(1):10380. PubMed ID: 28871133
[TBL] [Abstract][Full Text] [Related]
19. Invasive lobular carcinoma: an understudied emergent subtype of breast cancer.
Mouabbi JA; Hassan A; Lim B; Hortobagyi GN; Tripathy D; Layman RM
Breast Cancer Res Treat; 2022 Jun; 193(2):253-264. PubMed ID: 35347549
[TBL] [Abstract][Full Text] [Related]
20. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade.
Metzger-Filho O; Ferreira AR; Jeselsohn R; Barry WT; Dillon DA; Brock JE; Vaz-Luis I; Hughes ME; Winer EP; Lin NU
Oncologist; 2019 Jul; 24(7):e441-e449. PubMed ID: 30518616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]